• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Azitra Inc filed SEC Form 8-K: Shareholder Director Nominations

    5/2/25 4:05:14 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    false 0001701478 0001701478 2025-05-02 2025-05-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 2, 2025

     

    AZITRA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41705   46-4478536

    (State or other jurisdiction of

    incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    21 Business Park Drive

    Branford, CT 06405

    (Address of principal executive offices)(Zip Code)

     

    (203) 646-6446

    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock: Par value $0.0001   AZTR   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.08 Shareholder Director Nominations.

     

    On May 2, 2025, the board of directors of Azitra, Inc. (the “Company”) established that the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) will be held virtually on Monday, June 23, 2025 at 11:00 a.m. Eastern Time. The record date for the determination of stockholders of the Company entitled to receive notice of and to vote at the 2025 Annual Meeting shall be the close of business on May 28, 2025.

     

    Due to the fact that the date of the 2025 Annual Meeting is more than 30 days before the anniversary date of the 2024 Annual Meeting of Stockholders, the Company is providing the due date for submission of any qualified stockholder proposal or qualified stockholder nominations. Stockholders of the Company who wish to have a proposal considered for inclusion in the Company’s proxy materials for the 2025 Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 (the “Exchange Act”), must ensure that such proposal is received by the Company’s Secretary at its principal executive offices on or before the close of business on May 15, 2025, which the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials in accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Exchange Act. Any such proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission in order to be eligible for inclusion in the proxy materials for the 2025 Annual Meeting.

     

    In addition, in accordance with the requirements contained in the Company’s bylaws, stockholders of the Company who wish to bring business before the 2025 Annual Meeting outside of Rule 14a-8 of the Exchange Act or to nominate a person for election as a director must ensure that written notice of such proposal (including all information specified in the Company’s bylaws) is received by the Company’s Secretary at the Company’s principal executive offices no later than the close of business on May 12, 2025. Any such proposal must meet the requirements set forth in the Company’s bylaws to be brought before the 2025 Annual Meeting.

     

    In addition, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than our nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by May 12, 2025 and comply with the Company’s bylaws.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AZITRA, INC.
         
    Date: May 2, 2025 By: /s/ Francisco Salva
        Francisco Salva
        Chief Executive Officer

     

     

     

    Get the next $AZTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash

      Azitra plans to dose first patient in a Phase 1/2 trial in the first half of 2025 for its precision dermatology candidate ATR04-484, designed for the treatment of EGFR inhibitor-associated rash BRANFORD, Conn., May 14, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present a poster describing the Phase 1/2 clinical trial of ATR04-484 for EGFR inhibitor ("EGFRi")-associated rash at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). ASGCT is being held May 13-17, 2025, in New Orleans, Louisiana.

      5/14/25 4:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates

      BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update. Q1 2025 and Recent Business Highlights Announced acceptance of poster detailing the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingEntered into Purchase Agreement for up to $20 Mil

      5/13/25 5:06:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025

      Azitra is developing ATR04-484 for the treatment of EGFR inhibitor-associated rash with plans to dose first patient in Phase 1/2 trial in the first half of 2025 BRANFORD, Conn., April 25, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that an abstract detailing the Phase 1/2 clinical trial of ATR04-484 in EGFR inhibitor ("EGFRi")-associated rash has been accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2025 in Chicago.

      4/25/25 8:33:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

      4 - Azitra, Inc. (0001701478) (Issuer)

      4/1/24 9:51:59 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

      BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

      7/11/23 4:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Financials

    Live finance-specific insights

    See more
    • Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

      2/24/25 8:30:00 AM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

      BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

      11/12/24 5:05:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

      Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

      8/12/24 6:23:00 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Azitra Inc

      PRE 14A - Azitra, Inc. (0001701478) (Filer)

      5/19/25 4:30:39 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Azitra Inc

      SCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)

      5/14/25 2:52:17 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Azitra Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Azitra, Inc. (0001701478) (Filer)

      5/13/25 5:05:23 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:56:51 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/14/24 12:18:21 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Azitra Inc

      SC 13G/A - Azitra, Inc. (0001701478) (Subject)

      11/6/24 4:35:43 PM ET
      $AZTR
      Biotechnology: Pharmaceutical Preparations
      Health Care